When.com Web Search

  1. Ads

    related to: clinical diagnostics companies stock predictions

Search results

  1. Results From The WOW.Com Content Network
  2. Prediction: These 3 Healthcare Stocks Will Soar in 2025 - AOL

    www.aol.com/prediction-3-healthcare-stocks-soar...

    Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The ...

  3. Quest Diagnostics EPS Tops Predictions - AOL

    www.aol.com/finance/quest-diagnostics-eps-tops...

    Quest Diagnostics (NYSE:DGX), a leader in diagnostic testing and information services, released its fourth quarter results on Jan. 30. The company reported a notable quarter with adjusted earnings ...

  4. 3 Stocks That Could Trounce the Market in 2025 - AOL

    www.aol.com/finance/3-stocks-could-trounce...

    Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The ...

  5. SomaLogic - Wikipedia

    en.wikipedia.org/wiki/SomaLogic

    SomaLogic, Inc. is a protein biomarker discovery and clinical diagnostics company [1] located in Boulder, Colorado.It became listed on Nasdaq in September 2021 with a merger with the special-purpose acquisition company CM Life Sciences II, Inc. [2] The company was acquired by Standard BioTools in January 2024 in an all-stock deal.

  6. Prediction: These Could Be the Best-Performing Biotech Stocks ...

    www.aol.com/prediction-could-best-performing...

    Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The ...

  7. LifeScan - Wikipedia

    en.wikipedia.org/wiki/LifeScan

    LifeScan was established in 1981. [3] It was acquired by Johnson & Johnson (J&J) in 1986, [2] [4] and in June 2018, J&J agreed to sell LifeScan to Platinum Equity as part of its strategic exit from the diabetes device market, accepting an offer originally tendered in March 2018. [1]